The dash for MASH is gaining momentum, with Roche AG acquiring 89bio Inc. and its phase III FGF21 analogue, pegozafermin, for treating metabolic dysfunction-associated steatohepatitis, in a deal worth up to $3.5 billion. The Swiss pharma is to pay $14.50 per share, valuing San Francisco-based 89Bio at $2.4 billion, a premium of approximately 52% to 89bio\u2019s 60-day average price on Sept. 17, 2025. Shares of 89bio (NASDAQ:ETNB) gained $6.88, or 85%, to close Sept. 18 at $14.96.<\/p>\n
BioWorld<\/a> Clinical<\/a> Deals and M&A<\/a> Endocrine\/metabolic<\/a> Peptide<\/a> Europe<\/a> U.S.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"The dash for MASH is gaining momentum, with Roche AG acquiring 89bio Inc. and its phase III FGF21…\n","protected":false},"author":2,"featured_media":11348,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[8567,8086,8092,8568,8573,197,8566,8570,8571,8569,3265,8565,8572,5693,8574,134,4178,2278],"class_list":["post-11347","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-89bio-inc","tag-bioworld","tag-clinical","tag-deals-and-ma","tag-endocrine-metabolic","tag-europe","tag-fgf21-analogue","tag-fibroblast-growth-factor-21","tag-fibrosis","tag-gastrointestinal","tag-mash","tag-metabolic-dysfunction-associated-steatohepatitis","tag-obesity-related-comorbidities","tag-pegozafermin","tag-peptide","tag-roche","tag-roche-ag","tag-u-s"],"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/11347","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=11347"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/11347\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/11348"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=11347"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=11347"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=11347"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}